SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Eris Lifesciences - Quaterly Results

21 May 2024 Evaluate
The revenue zoomed 8.49% to Rs. 3412.96 millions for the quarter ended March 2024 as compared to Rs. 3145.84 millions during the corresponding quarter last year.Net Profit of the company move down -55.02% to Rs. 395.08  millions from Rs. 878.41 millions  in the same quarter last year.Operating Profit reported a sharp decline to 997.82 millions from 1157.50 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 3412.96 3145.84 8.49 14867.06 13307.25 11.72 14867.06 13307.25 11.72
Other Income 203.94 42.60 378.73 348.28 172.64 101.74 348.28 172.64 101.74
PBIDT 997.82 1157.50 -13.80 4886.42 5223.78 -6.46 4886.42 5223.78 -6.46
Interest 288.92 29.56 877.40 574.20 208.10 175.93 574.20 208.10 175.93
PBDT 708.90 1127.94 -37.15 4312.22 5015.68 -14.03 4312.22 5015.68 -14.03
Depreciation 291.42 172.84 68.61 1023.89 646.57 58.36 1023.89 646.57 58.36
PBT 417.48 955.10 -56.29 3288.33 4369.11 -24.74 3288.33 4369.11 -24.74
TAX 22.40 76.69 -70.79 291.21 389.03 -25.14 291.21 389.03 -25.14
Deferred Tax -59.97 -93.36 -35.76 -285.23 -375.93 -24.13 -285.23 -375.93 -24.13
PAT 395.08 878.41 -55.02 2997.12 3980.08 -24.70 2997.12 3980.08 -24.70
Equity 136.03 135.99 0.03 136.03 135.99 0.03 136.03 135.99 0.03
PBIDTM(%) 29.24 36.79 -20.54 32.87 39.26 -16.27 32.87 39.26 -16.27

Eris Lifesciences Share Price

1446.50 -18.90 (-1.29%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×